The immunostimulatory nature of mRNA lipid nanoparticles

P Sharma, D Hoorn, A Aitha, D Breier, D Peer - Advanced drug delivery …, 2024 - Elsevier
Abstract mRNA-Lipid nanoparticles (LNPs) are at the forefront of global medical research.
With the development of mRNA-LNP vaccines to combat the COVID-19 pandemic, the …

Innate immune mechanisms of mRNA vaccines

R Verbeke, MJ Hogan, K Loré, N Pardi - Immunity, 2022 - cell.com
The lipid nanoparticle (LNP)-encapsulated, nucleoside-modified mRNA platform has been
used to generate safe and effective vaccines in record time against COVID-19. Here, we …

Considerations on the design of lipid-based mRNA vaccines against cancer

S Meulewaeter, Y Zhang, A Wadhwa, K Fox… - Journal of Molecular …, 2024 - Elsevier
Throughout the last decades, mRNA vaccines have been developed as a cancer
immunotherapeutic and the technology recently gained momentum during the COVID-19 …

mRNA nanodelivery systems: targeting strategies and administration routes

M Yuan, Z Han, Y Liang, Y Sun, B He… - Biomaterials …, 2023 - spj.science.org
With the great success of coronavirus disease (COVID-19) messenger ribonucleic acid
(mRNA) vaccines, mRNA therapeutics have gained significant momentum for the prevention …

Advanced technologies for the development of infectious disease vaccines

A Gupta, A Rudra, K Reed, R Langer… - Nature Reviews Drug …, 2024 - nature.com
Vaccines play a critical role in the prevention of life-threatening infectious disease. However,
the development of effective vaccines against many immune-evading pathogens such as …

Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines

T Matsumura, T Takano… - International Immunology, 2023 - academic.oup.com
Vaccination for the prevention of severe acute respiratory syndrome coronavirus type 2
(SARS-CoV-2) infection is considered the most promising approach to control the pandemic …

COVID-19 modified mRNA “vaccines”: Lessons learned from clinical trials, mass vaccination, and the bio-pharmaceutical complex, Part 2

MN Mead, S Seneff, J Rose, R Wolfinger… - International Journal of …, 2024 - ijvtpr.com
The COVID-19 modified mRNA (modmRNA) lipid nanoparticle-based “vaccines” are not
classical antigen-based vaccines but instead prodrugs informed by gene therapy …

Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines

KH Bae, B Shunmuganathan, L Zhang, A Lim, R Gupta… - npj Vaccines, 2024 - nature.com
The advent of SARS-CoV-2 variants with defined mutations that augment pathogenicity
and/or increase immune evasiveness continues to stimulate global efforts to improve …

Genome‐wide association studies of response and side effects to the BNT162b2 vaccine in Italian healthcare workers: Increased antibody levels and side effects in …

C Magri, E Marchina, E Sansone, AP D'Adamo… - HLA, 2023 - Wiley Online Library
The remarkable variability of response to vaccines against SARS‐CoV‐2 is apparent. The
present study aims to estimate the extent to which the host genetic background contributes …

[HTML][HTML] Single-epitope T cell–based vaccine protects against SARS-CoV-2 infection in a preclinical animal model

T Tada, JY Peng, BM Dcosta, NR Landau - JCI insight, 2023 - ncbi.nlm.nih.gov
Currently authorized COVID-19 vaccines induce humoral and cellular responses to epitopes
in the SARS-CoV-2 spike protein, though the relative roles of antibodies and T cells in …